The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Open accessAbstract
On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Costante, G., Meringolo, D., Durante, C., Bianchi, D., Nocera, M., Tumino, S., Crocetti, U., Attard, M., Maranghi, M., Torlontano, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1590 · Cited by 372
Guidelines for Combining Neoplasms for Evaluation of Rodent Carcinogenesis Studies
McConnell, E. E., Solleveld, H. A., Swenberg, J. A., & Boorman, G. A. (1988) · Carcinogenicity · doi:10.1007/978-3-642-61364-7_21 · Cited by 189
Research works printed but not linked: 1
- McConnell EE, 1986, J Natl Cancer Inst, 76, 283
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Metadata
- Authors
- Parks, M., & Rosebraugh, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 774-777
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058922633
- Cited by
- 275
- References
- 3
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy. https://app.cochat.ai/papers/10.1056/nejmp1001578
- The paper
- Parks, M., & Rosebraugh, C. (2010). Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejmp1001578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.